Brokerages Expect Alnylam Pharmaceuticals, Inc. (ALNY) Will Post Earnings of -$1.53 Per Share

Equities research analysts expect that Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) will post earnings of ($1.53) per share for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Alnylam Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($1.47) and the lowest estimate coming in at ($1.58). Alnylam Pharmaceuticals reported earnings per share of ($1.07) in the same quarter last year, which would suggest a negative year over year growth rate of 43%. The business is scheduled to issue its next quarterly earnings results on Wednesday, August 8th.

According to Zacks, analysts expect that Alnylam Pharmaceuticals will report full-year earnings of ($6.05) per share for the current fiscal year, with EPS estimates ranging from ($6.33) to ($5.64). For the next year, analysts anticipate that the business will post earnings of ($4.85) per share, with EPS estimates ranging from ($5.48) to ($3.70). Zacks’ EPS calculations are a mean average based on a survey of research firms that cover Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.47) by $0.06. Alnylam Pharmaceuticals had a negative net margin of 565.20% and a negative return on equity of 36.81%. The company had revenue of $21.90 million during the quarter, compared to the consensus estimate of $35.23 million. During the same period in the prior year, the firm earned ($1.25) earnings per share. Alnylam Pharmaceuticals’s revenue was up 15.3% on a year-over-year basis.



A number of equities analysts recently issued reports on the stock. ValuEngine downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday. BidaskClub lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, June 18th. Zacks Investment Research lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, May 10th. Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals to $118.00 and set an “equal weight” rating for the company in a report on Monday, May 7th. Finally, BMO Capital Markets reduced their price target on shares of Alnylam Pharmaceuticals from $160.00 to $134.00 and set an “outperform” rating for the company in a report on Friday, May 4th. Two analysts have rated the stock with a sell rating, four have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $140.38.

In other Alnylam Pharmaceuticals news, COO Yvonne Greenstreet sold 7,221 shares of the company’s stock in a transaction that occurred on Monday, March 26th. The shares were sold at an average price of $136.54, for a total transaction of $985,955.34. Following the transaction, the chief operating officer now owns 7,221 shares in the company, valued at approximately $985,955.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laurie Keating sold 1,563 shares of the company’s stock in a transaction that occurred on Wednesday, June 20th. The shares were sold at an average price of $105.04, for a total transaction of $164,177.52. Following the transaction, the senior vice president now owns 16,063 shares in the company, valued at approximately $1,687,257.52. The disclosure for this sale can be found here. Insiders own 4.30% of the company’s stock.

Institutional investors have recently modified their holdings of the business. Aperio Group LLC grew its holdings in Alnylam Pharmaceuticals by 24.7% in the 4th quarter. Aperio Group LLC now owns 21,078 shares of the biopharmaceutical company’s stock valued at $2,678,000 after buying an additional 4,170 shares during the last quarter. Teacher Retirement System of Texas grew its stake in Alnylam Pharmaceuticals by 256.4% in the fourth quarter. Teacher Retirement System of Texas now owns 24,050 shares of the biopharmaceutical company’s stock valued at $3,056,000 after acquiring an additional 17,302 shares during the period. California Public Employees Retirement System grew its stake in Alnylam Pharmaceuticals by 47.2% in the fourth quarter. California Public Employees Retirement System now owns 196,038 shares of the biopharmaceutical company’s stock valued at $24,907,000 after acquiring an additional 62,832 shares during the period. Daiwa Securities Group Inc. acquired a new position in Alnylam Pharmaceuticals in the fourth quarter valued at about $343,000. Finally, KBC Group NV grew its stake in Alnylam Pharmaceuticals by 709.5% in the fourth quarter. KBC Group NV now owns 7,666 shares of the biopharmaceutical company’s stock valued at $974,000 after acquiring an additional 6,719 shares during the period. Institutional investors and hedge funds own 90.21% of the company’s stock.

Alnylam Pharmaceuticals traded up $1.51, reaching $104.20, during trading on Tuesday, Marketbeat Ratings reports. The company had a trading volume of 711,365 shares, compared to its average volume of 623,621. Alnylam Pharmaceuticals has a 52 week low of $70.76 and a 52 week high of $153.99. The company has a market cap of $10.32 billion, a P/E ratio of -19.23 and a beta of 2.67. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.61 and a quick ratio of 14.61.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.

Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply